As of January 22, 2026, the soft mist inhalers market is identifying as the fastest-growing segment of the respiratory drug delivery landscape, with its 2026 valuation reaching approximately $3.32 billion. The 2026 landscape is defined by a robust CAGR of 7.9% to 14.3%, as these devices gain significant traction over traditional pressurized metered-dose inhalers (pMDIs) and dry powder inhalers...